Briacell Therapeutics
BCTX
23 hedge funds and large institutions have $14.6M invested in Briacell Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 1 closing their positions.
1,793% more call options, than puts
Call options by funds: $4.6M | Put options by funds: $243K
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
28% more funds holding
Funds holding: 18 → 23 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.38% less ownership
Funds ownership: 16.98% → 15.6% (-1.4%)
14% less capital invested
Capital invested by funds: $17M → $14.6M (-$2.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$144K |
| 2 |
OBWG
Onyx Bridge Wealth Group
Tarrytown,
New York
|
+$144K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$78.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$71.8K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$71.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$1.18M |
| 2 |
N
Natixis
Paris,
France
|
-$350K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$156K |
| 4 |
Morgan Stanley
New York
|
-$144K |
| 5 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$20.8K |
BCTX Hedge Fund Activity: Q4 2023 in Review
23 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q4 2023, worth a combined $14.6M — down 14% from $17M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCTX positions and 1 closed out — a net gain of 5 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Marex Group, opening a new position worth an estimated $144K. The largest seller was Wasatch Advisors, cutting an estimated $1.18M.
- 23 institutional investors held Briacell Therapeutics (BCTX) as of Q4 2023, up from 18 in Q3 2023.
- Funds reported $14.6M of Briacell Therapeutics stock for Q4 2023, down 14% quarter-over-quarter.
- 6 funds opened new Briacell Therapeutics positions in Q4 2023 and 1 closed out, a net change of +5 holders.
- The largest Briacell Therapeutics buyer in Q4 2023 was Marex Group, an estimated $144K added.
- The largest Briacell Therapeutics seller in Q4 2023 was Wasatch Advisors, an estimated $1.18M sold.
Based on aggregated 13F filings for Q4 2023.